Peter Feinberg bought $87k of IMRX
director at Immuneering Corp. 20,000 shares at an average of $4.35, traded Jan 12, 2026, filed Jan 14, 2026.
Score components
- +15RoleDirector
- +9Trade size$87k at market
- +3Relative to holdingsHoldings up 17%
- +8Price context54% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +11.3%, 3m +29.8%, 6m +16.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001790340-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | POpen-market purchase Class A Common Stockindirect: General Partner of S4K Investments LLC. | +20,000 | $4.35 | $87k | 135,441 | Jan 14, 2026 |
Related signals
Other insiders at Immuneering Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Immuneering Corp | Benjamin J. Zeskind PRESIDENT AND CEO | $11k 2,400 shares | +0% | |
| 36Weak | Immuneering Corp | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | $25k 6,035 shares | +2% | |
| 48Moderate | Immuneering Corp | Harold Eugene Brakewood Chief Business Officer | $25k 5,250 shares | +91% | |
| 54Moderate | Immuneering Corp | Thomas J. Schall director | $101k 21,645 shares | +41% | |
| 33Weak | Immuneering Corp | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | $11k 2,298 shares | +1% | |
| 41Moderate | Immuneering Corp | Leah R Neufeld CHIEF PEOPLE OFFICER | $11k 2,626 shares | +11% | |
| 45Moderate | Immuneering Corp | Peter Feinberg director | $50k 7,500 shares | +5% | |
| 36Weak | Immuneering Corp | Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | $6,967 1,020 shares | +26% | |
| 30Weak | Immuneering Corp | Leah R Neufeld CHIEF PEOPLE OFFICER | $5,103 800 shares | +4% | |
| 30Weak | Immuneering Corp | Mallory Morales Chief Accounting Officer | $1,917 300 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.